XORTX THERAPEUTICS INC (XRTX) Stock Price, Quote, News and Overview
NASDAQ:XRTX - Nasdaq - CA98420Q3061 - Common Stock - Currency: USD
XRTX Quote, Performance and Key Statistics
XORTX THERAPEUTICS INC
NASDAQ:XRTX (2/5/2025, 3:06:44 PM)
0.89
-0.02 (-2.2%)
The current stock price of XRTX is 0.89 USD. In the past month the price decreased by -24.17%. In the past year, price decreased by -59.91%.
XRTX Latest News, Press Releases and Analysis
What's going on in today's pre-market session
Stay updated with the stocks that are on the move in Thursday's pre-market session.
XORTX to Present at Microcap Conference
CALGARY, Alberta, Jan. 29, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (
XORTX Announces Change of Auditor
CALGARY, Alberta, Jan. 17, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (
XORTX Strengthens Executive Team
Dr. Michael Bumby joins XORTX as Chief Financial Officer...
XORTX Announces Presentation at the Rare and Genetic Disease Summit
CALGARY, Alberta, Dec. 12, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (
XORTX Announces Closing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement
CALGARY, Alberta, Oct. 18, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (
XRTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 82.99 | 801.23B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 29.12 | 381.45B | ||
| JNJ | JOHNSON & JOHNSON | 15.45 | 371.66B | ||
| MRK | MERCK & CO. INC. | 11.8 | 228.05B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.86 | 219.46B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.52 | 218.77B | ||
| PFE | PFIZER INC | 8.52 | 150.19B | ||
| SNY | SANOFI-ADR | 13.52 | 134.20B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 51.24 | 121.59B | ||
| ZTS | ZOETIS INC | 30.56 | 79.41B | ||
| GSK | GSK PLC-SPON ADR | 9.11 | 76.96B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.09 | 42.39B |
Related stock screener links
About XRTX
Company Profile
XORTX Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in Calgary, Alberta. The company went IPO on 2015-09-30. The firm develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. The company is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The firm has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The firm's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.
Company Info
XORTX THERAPEUTICS INC
3710 - 33rd Street NW
Calgary ALBERTA CA
Employees: 3
Company Website: https://www.xortx.com/
Investor Relations: http://www.apacresources.com/en_US/ir.html
Phone: 14034557727
XRTX FAQ
What is the stock price of XRTX?
The current stock price of XRTX is 0.89 USD.
What is the symbol for XORTX THERAPEUTICS INC stock?
The exchange symbol of XORTX THERAPEUTICS INC is XRTX and it is listed on the Nasdaq exchange.
On which exchange is XRTX stock listed?
XRTX stock is listed on the Nasdaq exchange.
Is XRTX a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for XRTX, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of XRTX.
Does XRTX stock pay dividends?
XRTX does not pay a dividend.
What is the Price/Earnings (PE) ratio of XRTX?
XRTX does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.04).
What is the Short Interest ratio of XRTX stock?
The outstanding short interest for XRTX is 2.75% of its float.
XRTX Technical Analysis
XRTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to XRTX. XRTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
XRTX Financial Highlights
Over the last trailing twelve months XRTX reported a non-GAAP Earnings per Share(EPS) of -0.04. The EPS decreased by 98.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -19.13% | ||
| ROE | -34.53% | ||
| Debt/Equity | 0 |
XRTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to XRTX. The Buy consensus is the average rating of analysts ratings from 5 analysts.